- Report
- January 2024
- 150 Pages
Global
From €5640EUR$5,950USD£4,711GBP
- Report
- August 2022
- 120 Pages
Global
From €4265EUR$4,500USD£3,563GBP
- Report
- November 2021
- 101 Pages
Global
From €4265EUR$4,500USD£3,563GBP
- Report
- January 2024
- 109 Pages
United States
€3317EUR$3,500USD£2,771GBP
- Report
- February 2018
- 680 Pages
Global
From €20852EUR$22,000USD£17,420GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €474EUR$500USD£396GBP
Singulair is a prescription medication used to treat asthma and allergies. It is a leukotriene receptor antagonist, which works by blocking the action of leukotrienes, a type of chemical that can cause inflammation in the lungs. Singulair is also used to prevent exercise-induced bronchoconstriction, a narrowing of the airways that can occur during physical activity. It is available in tablet, chewable tablet, and granule form.
Singulair is part of a larger class of respiratory drugs known as bronchodilators, which are used to treat asthma and other respiratory conditions. Other bronchodilators include albuterol, ipratropium, and theophylline. These drugs work by relaxing the muscles in the airways, allowing air to flow more freely.
Singulair is a popular choice for treating asthma and allergies, as it is effective and has few side effects. It is also used to treat chronic obstructive pulmonary disease (COPD) and other respiratory conditions.
Companies in the Singulair market include Merck & Co., Inc., Teva Pharmaceuticals, and Mylan N.V. Show Less Read more